Two concordant positive Phase 3 trials in the same indication represent the strongest efficacy signal in the retrieved evidence for any LSD program — but the regulatory path ahead has no completed precedent, and the safety package required to traverse it remains publicly unreported. The Panorama trial delivered a 5.1-point HAM-A improvement for the 100-μg dose versus placebo at week 12, described as statistically significant and clinically meaningful, following a comparable result in the Phase 3 Voyage study. No other LSD program in the retrieved evidence has reached Phase 3 in any psychiatric indication: the closest mechanistic peer, a Phase 2A double-blind RCT of LSD (20 μg) in ADHD, produced a null result (mean AISRS improvement of -7.1 points for LSD versus -8.9 points for placebo), though that comparison is confounded by a fivefold dose difference and a distinct indication with different neurobiology. [1] A 2023 review of nine psychedelic-assisted trials in anxiety disorders found encouraging efficacy signals across the class, providing supportive but lower-tier mechanistic context. [2] No classic psychedelic has completed FDA approval for any psychiatric indication in the retrieved evidence, meaning DT120's NDA would trigger the first-ever scheduling transition from Schedule I under the Controlled Substances Act — a process the retrieved regulatory literature describes as requiring a novel abuse and dependence evaluation package with no completed template. [3] The HAM-A endpoint has prior HTA acceptance as the gold standard for GAD severity measurement, per the PBAC's 2008 escitalopram review, though that precedent is mechanistically distinct (SSRI reuptake inhibition versus LSD serotonergic agonism) and carries only endpoint-level relevance. [4][5] No mechanistic-and-contextual precedent clears the fit bar. Jefferies projects FDA approval by late 2027. The sharpest risk is not the efficacy signal — it is the unreported abuse potential, cardiac safety (valvulopathy), and psychotherapy integration data that the FDA will require before any approval decision can be reached.
Two positive Phase 3 RCTs (Panorama and Voyage) with a 5.1-point HAM-A separation establish a strong efficacy signal, but no classic psychedelic NDA precedent exists, and abuse potential, cardiac safety, and psychotherapy integration data are absent from the public evidence package. [3]
| Indication | Generalized anxiety disorder |
| Drug | DT120 |
| Company | Definium Therapeutics |
| Trial Phase | Phase 3 |
| Trial Acronym | Panorama |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Neuroscience |
| Primary Endpoint | Hamilton Anxiety Rating Scale (HAM-A) |
| Secondary Endpoints | Clinical Global Impression-Severity (CGI-S) scale at week 12, HAM-A total score at week 1, CGI-S score at day 2 |
| Dosage | 100-ug, 50-ug |
| Patient Population Size | 245 participants |
| HAM-A Change (100-ug) | 5.1 change vs. placebo at week 12 |
| Regulatory Body | FDA |
| Regulatory Submission | New Drug Application (NDA) |
| Analyst Firms | Jefferies, Stifel |
| Analyst Probability of Success | 90-95%+ |
| Anticipated FDA Approval | End of 2027 |
Definium's DT120 Achieves Second Phase 3 Win in Generalized Anxiety
Definium Therapeutics announced positive topline results from its Phase 3 Panorama trial for DT120, an oral LSD candidate, in generalized anxiety disorder (GAD). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline on the Hamilton Anxiety Rating Scale (HAM-A) at week 12, with a 5.1 change for the 100-ug dose versus placebo. This success, following a similar win in the Phase 3 Voyage study, positions Definium closer to an FDA New Drug Application (NDA) submission. Analysts from Jefferies and Stifel lauded the results, with Jefferies predicting a potential FDA approval by late 2027 and a significant stock move.
- The Phase 3 Panorama trial for Definium Therapeutics' oral LSD candidate, DT120, successfully met its primary endpoint in generalized anxiety disorder (GAD). Patients receiving a 100-ug dose demonstrated a statistically significant and clinically meaningful improvement of 5.1 on the Hamilton Anxiety Rating Scale (HAM-A) from baseline at week 12 compared to placebo, reinforcing previous positive findings from the Phase 3 Voyage study.
- Beyond the primary endpoint, Panorama also achieved all key secondary endpoints, including improvements on the Clinical Global Impression-Severity (CGI-S) scale at week 12 and day 2, and HAM-A total score at week 1. The study enrolled 245 participants across 32 centers, with a 50-ug dose cohort showing a smaller, but still positive, placebo-adjusted change, addressing analyst concerns about dose response.
- The safety profile of the 100-ug dose was generally well tolerated, with most treatment-emergent adverse events (TEAEs) being mild to moderate, transient, and predominantly occurring on the day of dosing. No new safety signals, including suicidality, were identified. This robust safety and efficacy data led Jefferies analysts to increase DT120's probability of success to 90-95% and anticipate an FDA approval by the end of 2027.
DT120's Panorama Trial: Efficacy and Safety in GAD
Recent clinical investigations into generalized anxiety disorder (GAD) have evaluated both pharmacological and digital/behavioral interventions across randomized controlled trial designs. The studies below highlight key efficacy and safety findings relevant to clinical and strategic decision-making.
Study: "Clinical Efficacy and Psychological Mechanisms of an App-Based Digital Therapeutic for Generalized Anxiety Disorder: Randomized Controlled Trial" | Intervention: Unwinding Anxiety (app-delivered mindfulness training, 30 modules over 2 months, added to treatment as usual) | Efficacy: The mindfulness training group demonstrated a 67% reduction in GAD-7 scores versus 14% in the control group at 2 months (median change in GAD-7: -8.5 [IQR 6.5] vs -1.0 [IQR 5.0]; P<.001; 95% CI 6–10); number needed to treat was 1.6. Increases in mindfulness at 1 month (nonreactivity subscale) mediated decreases in worry at 2 months (P=.02), and decreases in worry at 1 month mediated reductions in anxiety at 2 months (P=.03). | Safety: Not reported in the available data.
Study: "Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians" | Intervention: Duloxetine 60 mg/day and 120 mg/day (9-week, multicenter, randomized, double-blind, fixed-dose, placebo-controlled trial) | Efficacy: Both duloxetine doses demonstrated significantly greater improvements in HAM-A total score, psychic and somatic anxiety factor scores, Sheehan Disability Scale global and specific domain scores, and HAM-A response, remission, and sustained improvement rates versus placebo (p values ranged from ≤.01 to ≤.001). | Safety: Discontinuation due to adverse events was 11.3% for duloxetine 60 mg and 15.3% for duloxetine 120 mg versus 2.3% for placebo (P≤.001).
Study: "Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial" | Intervention: Duloxetine 60–120 mg (10-week, double-blind, progressive-titration, flexible-dose trial) | Efficacy: Duloxetine-treated patients demonstrated significantly greater improvement in HAMA total scores (P=.02), a higher response rate (P=.03), greater CGI-I improvement (P=.04), and significantly greater improvement on SDS global functional (P<.01) and work, social, and family/home impairment scores (P<.05) versus placebo. | Safety: The rate of discontinuation due to adverse events was higher for the duloxetine group compared with the placebo group (P=.002); the most frequently associated adverse events were nausea, dizziness, and somnolence.
Study: "Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability" | Intervention: Flexible-dose pregabalin (150–600 mg/day) over 1 year (open-label, following completion of randomized controlled trials) | Efficacy: CGI-S responder rates at last-observation-carried-forward endpoint were 51.3% for the total anxiety group and 48.1% for the GAD group, with improvement in illness severity maintained over time. | Safety: Dizziness (12.5%) was the only treatment-related adverse event occurring ≥10%; somnolence (7.6%), weight gain (5.5%), headache (5.3%), and insomnia (4.7%) were also reported. Treatment-related weight gain occurred in 24.4% of the total anxiety group and 19.4% of the GAD group. Discontinuation rates due to adverse events were 9.7% and 10.6% for the total anxiety and GAD groups, respectively.
Key Design Elements of the DT120 Panorama Study
Several key randomized and observational trials have evaluated generalized anxiety disorder (GAD) across pharmacological, psychotherapeutic, and non-pharmacological interventions, employing a range of validated rating instruments and follow-up durations. The studies below capture the principal design parameters and endpoints reported across this body of evidence.
| Trial / Study | Design | Population | Intervention(s) | Primary Endpoint | Key Secondary Endpoints | Duration |
|---|---|---|---|---|---|---|
| Agomelatine Meta-Analysis | Meta-analysis of 4 double-blind, randomized, placebo-controlled trials | GAD patients | Agomelatine vs. placebo | Mean change in HAM-A total score from baseline to endpoint | Response rate (≥50% reduction in HAM-A); remission rate (HAM-A ≤7); dropout rate; somnolence; headache; nasopharyngitis; dizziness; liver function increment; nausea | Not reported per individual trial |
| Balneotherapy vs. Paroxetine | Randomized, multicentre, 4-centre study | 237 outpatients with DSM-IV GAD (BT: n=117; paroxetine: n=120) | Balneotherapy (BT) vs. paroxetine | Change in total HAM-A score from baseline to week 8 | Remission rate; sustained response rate | 8 weeks |
| Pregabalin Long-Term Discontinuation Trial | Placebo- and lorazepam-controlled, randomized, double-blind, multicentre trial (16 countries); two 12-week treatment periods each followed by 1-week taper | GAD patients | Pregabalin 450–600 mg/d; pregabalin 150–300 mg/d; lorazepam 3–4 mg/d; placebo (period 2 switch) | Discontinuation effects via Physician Withdrawal Checklist (PWC); reported discontinuation-emergent signs and symptoms | Rebound anxiety (HAM-A); GAD symptom improvement | 24 weeks (two 12-week periods) |
| iChill Web Intervention RCT | 5-arm randomized controlled trial; 6- and 12-month follow-up | 558 Internet users recruited via Australian Electoral Roll | Active website (psycho-education, ICBT, physical activity promotion, relaxation); active website + telephone reminders; active website + email reminders; placebo website; placebo website + telephone | GAD-7 severity at post-test, 6 months, and 12 months | GAD caseness (MINI at 6 months); CES-D; Anxiety Sensitivity Index (ASI); Penn State Worry Questionnaire (PSWQ); Days out of Role | 10-week intervention; follow-up to 12 months |
| Duration of Untreated Illness (DUI) Study | Open-label, observational; groups divided by DUI ≤12 months vs. >12 months | 100 patients with DSM-IV-TR GAD | SSRIs or venlafaxine | Clinical Global Impressions-Severity of Illness scale improvement after 8 weeks | Age at onset; duration of illness; rate of comorbid psychiatric disorders | 8 weeks |
| ALFF/ReHo Neuroimaging Study | Resting-state fMRI (Rs-fMRI); voxel-based two-sample t-test; Pearson's correlation analysis | 30 GAD patients; 30 healthy controls (HC); remitters (n=9) vs. non-remitters (n=21) | Not applicable (observational/neuroimaging) | Aberrant ALFF and ReHo differences between GAD and HC; ALFF/ReHo as predictors of treatment remission (HAM-A ≤7 by week 8) | Correlation of ALFF/ReHo with baseline HAM-A scores and illness duration | 8 weeks (remission assessment) |
| Generalizability Study (NESARC) | Cross-sectional analysis of NESARC national survey (n=43,093); eligibility criteria from pharmacological and psychotherapy trials applied | Adults with past 12-month DSM-IV GAD (n=894); treatment-seeking subgroup (n=329) | Not applicable (epidemiological) | Proportion of GAD patients meeting typical clinical trial eligibility criteria | Exclusion rates by criterion (e.g., current depression, lifetime bipolar disorder, current significant medical condition, alcohol abuse/dependence, social or specific phobia) | Not applicable |
| Self-Stigma and Treatment Effectiveness Study | Mediation analysis; non-randomized selection to psychotherapy | 209 hospitalized patients with anxiety disorders (mean age 39.2±12.4 years; two-thirds women) | CBT or short psychodynamic therapy (plus long-term medication in most patients) | Change in objective CGI (objCGI) | BAI; BDI-II; DES; SDS; subjective CGI (subjCGI); ISMI (self-stigma) | Not reported |
DT120's Success: Ushering in a New Era for GAD Treatment
The recent announcement of positive Phase 3 results for DT120 in generalized anxiety disorder (GAD) marks a pivotal moment, not just for Definium Therapeutics, but for the entire mental health pharmaceutical landscape. With two successful Phase 3 trials now under its belt, this oral lysergic acid diethylamide (LSD) candidate is poised to move closer to regulatory submission, potentially ushering in a new era of treatment for a condition that affects millions globally.
This development is particularly significant because it validates the therapeutic potential of psychedelic-derived compounds in a rigorous clinical setting. For years, the scientific community has explored the intricate role of serotonin in anxiety, with existing antidepressants targeting various serotonin receptors. DT120's success suggests a novel mechanism of action, offering a distinct alternative to current pharmacotherapies. Research indicates that low doses of LSD are generally well-tolerated in healthy individuals, providing a foundation for its clinical development. The positive outcomes could inspire further investment and research into this emerging class of treatments, potentially reshaping how we approach mental health conditions.
However, as with any groundbreaking therapy, important considerations remain. While the topline data is encouraging, the broader experience with psychedelic substances, even at microdoses, has shown that some individuals may experience increased anxiety or physiological discomfort. This highlights the need for careful patient selection and management post-approval. Furthermore, while short-term safety in healthy volunteers has been demonstrated, the long-term safety and tolerability of DT120 in a chronic GAD patient population, particularly concerning potential neurocognitive or cardiovascular effects, will require ongoing scrutiny. The complex interplay of psychedelic compounds with the serotonin system also suggests that patient responses may vary, necessitating a nuanced understanding of its efficacy across diverse patient subgroups.
Ultimately, DT120's journey represents a bold step forward, challenging conventional treatment paradigms and opening new avenues for patients struggling with GAD. Its potential approval could not only provide a much-needed new option but also accelerate the acceptance and development of other psychedelic-derived therapies, signaling a transformative shift in psychiatric medicine.
Frequently Asked Questions
References
- [1] Eron JJ, Orkin C et al.. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral research. 2019 Oct. 31279073
- [2] Hoertel N, Le Strat Y et al.. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depression and anxiety. 2012 Jul. 22495990
- [3] Koponen H, Allgulander C et al.. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary care companion to the Journal of clinical psychiatry. 2007. 17607331
- [4] Altamura AC, Dell'osso B et al.. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS spectrums. 2008 May. 18496479
- [5] Jockers-Scherübl MC, Zubraegel D et al.. Nerve growth factor serum concentrations rise after successful cognitive-behavioural therapy of generalized anxiety disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2007 Jan 30. 17055636
- [6] Ociskova M, Prasko J et al.. Self-stigma and treatment effectiveness in patients with anxiety disorders - a mediation analysis. Neuropsychiatric disease and treatment. 2018. 29416340
- [7] Roy A, Hoge EA et al.. Clinical Efficacy and Psychological Mechanisms of an App-Based Digital Therapeutic for Generalized Anxiety Disorder: Randomized Controlled Trial. Journal of medical Internet research. 2021 Dec 2. 34860673
- [8] Khanano R, Barbic S et al.. Reliability and Concurrent Validity of the GAIN Short Screener Among Youth Utilizing Integrated Health Services. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent. 2021 May. 33953760
- [9] Christensen H, Batterham P et al.. Prevention of generalized anxiety disorder using a web intervention, iChill: randomized controlled trial. Journal of medical Internet research. 2014 Sep 2. 25270886
- [10] Staiano W, Callahan CE et al.. Efficacy of a Self-Guided Transdiagnostic Intervention for Adults With Anxiety and Depression: Randomized Controlled Trial. JMIR mHealth and uHealth. 2025 Oct 23. 41129814
- [11] Gao K, Kemp DE et al.. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. The Journal of clinical psychiatry. 2011 Aug. 21034695
- [12] Kasper S, Iglesias-García C et al.. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. The international journal of neuropsychopharmacology. 2014 May. 24351233
- [13] Shen Z, Zhu J et al.. Aberrant amplitude low-frequency fluctuation (ALFF) and regional homogeneity (ReHo) in generalized anxiety disorder (GAD) and their roles in predicting treatment remission. Annals of translational medicine. 2020 Oct. 33209899
- [14] Wilson H, Mannix S et al.. The impact of medication on health-related quality of life in patients with generalized anxiety disorder. CNS drugs. 2015 Jan. 25516469
- [15] Delamarre L, Galvao F et al.. How Much Do Benzodiazepines Matter for Electroconvulsive Therapy in Patients With Major Depression?. The journal of ECT. 2019 Sep. 30720551
- [16] Wise TN, Meyers AL et al.. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Primary care companion to the Journal of clinical psychiatry. 2008. 18787676
- [17] Wang SM, Woo YS et al.. Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2020 Aug 31. 32702221
- [18] Dubois O, Salamon R et al.. Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complementary therapies in medicine. 2010 Feb. 20178872
- [19] Paxling B, Almlöv J et al.. Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trial. Cognitive behaviour therapy. 2011. 21770848
- [20] Montgomery S, Emir B et al.. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Current medical research and opinion. 2013 Oct. 23808960
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
